XpressO-Melanoma: An Explainable Deep Learning Model for the Prediction of BRAF V600 Mutation Status in Cutaneous Melanomas

Publication date: Jul 06, 2025

BRAF V600E mutations are critical oncogenic drivers in cutaneous melanoma, influencing treatment decisions and outcomes. However, conventional molecular assays face limitations, including tissue availability, cost, and access. To address this, we present an explainable deep learning model that predicts BRAF V600E mutation status directly from diagnostic whole-slide images (WSIs) of skin cutaneous melanoma. Using histopathological WSIs from The Cancer Genome Atlas (TCGA) and their corresponding mutation labels (BRAF wildtype vs. BRAF V600E), we trained a weakly supervised deep learning pipeline, XpressO, to identify tumor regions of interest (ROIs) predictive of BRAF mutation status. The model outputs attention heatmaps highlighting spatially relevant diagnostic features and computes a combined probability score from the top ten attention regions per WSI. These regions are further reviewed by a pathologist for biological appropriateness. On an independent test set, the model achieved an AUC of 0.79 with balanced precision and recall, correctly identifying 7 of 8 BRAF V600E mutant cases. This demonstrates the model’s ability to capture phenotypic correlates of mutation status and highlights the potential of computational pathology in precision oncology. Our approach offers a scalable, interpretable, and cost-effective alternative to molecular testing, particularly in resource-limited settings.

PDF

Concepts Keywords
Biopsy Al
Invasive Attention
July Braf
Mutants Bvw
X2580_splice Figure
Learning
Melanoma
Mutant
Mutation
Preprint
Regions
Status
Tumor
V600e
Wild

Semantics

Type Source Name
disease MESH Melanoma
pathway KEGG Melanoma
disease MESH Cancer
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Coenzyme M
drug DRUGBANK L-Valine
drug DRUGBANK Glutamic Acid
disease MESH Neuroblastoma
drug DRUGBANK Rasagiline
disease MESH skin cancers
disease MESH clinical importance
pathway KEGG MAPK signaling pathway
disease MESH metastasis
disease MESH lung adenocarcinomas
disease MESH microsatellite instability
disease MESH colorectal carcinoma
disease MESH necrosis
disease MESH oncogenesis
disease MESH uncertainty
drug DRUGBANK Aspartame
disease MESH confusion
drug DRUGBANK Sulpiride
disease MESH Mutation Frequency
drug DRUGBANK Saquinavir
drug DRUGBANK Cobimetinib
drug DRUGBANK Vemurafenib
drug DRUGBANK Fenamole

Download Document

(Visited 7 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *